arrow
F

Florestan Koll

hospital of the goethe university frankfurt
H指数:12
被引数:464

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT)

局部晚期膀胱癌根治性膀胱切除术前放化疗联合免疫治疗:一项前瞻性、单臂、多中心、II期临床试验(RACE-IT)

2026-02-260
OAAI
Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma

结合分子模式与临床数据,以改进转移性尿路上皮癌中免疫检查点抑制剂的预测效果

2025-11-120
OAAI
FGFR1/3 Signaling as an Achilles’ Heel of Phenotypic Diversity in Urothelial Carcinoma

FGFR1/3信号作为尿路上皮癌表型多样性的阿喀琉斯之踵

2025-07-280
OAAI
Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract

尿路上皮透明细胞腺癌的全面分子、病理学和临床特征分析

2025-06-180
PRE
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy

177Lu-PSMA放射性配体疗法在一线ARPI治疗后的紫杉烷类初治的转移性去势抵抗性前列腺癌的一线和二线治疗中

2025-01-131
OA
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

中和GDF-15可以克服实体瘤中抗PD-1和抗PD-L1的耐药性

Nature
IF48.5
2024-12-110
OAAI
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer

真实世界比较:卡巴他赛与177Lu-PSMA放射性药物疗法在转移性去势抵抗性前列腺癌中的应用

2024-11-143
PRE
Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients

转移性激素敏感型前列腺癌和一至六线转移性去势抵抗性前列腺癌患者的当代治疗模式和肿瘤学结果

2024-08-018
OAAI
Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany
2024-03-013
OAAI
RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) - first results
2022-09-014
OAAI